The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Toward Quality Care in ADHD: Defining the Goals of Treatment
Abstract
Objective: Therapeutic goals for chronic mental disorders like major depressive disorder (MDD) and schizophrenia have evolved in parallel with the growing medical knowledge about the course and treatment of these disorders. Although the knowledge base regarding the clinical course of ADHD, a chronic psychiatric disorder, has evolved beyond symptomatic improvement and short-term treatment response, long-term goals, such as functional remission, have not yet been clearly defined. Method: A PubMed literature search was conducted to investigate the therapeutic goals of pharmacologic treatment referenced in the published literature from January 1998 through February 2010 using the following commonly used ADHD treatments as keywords: amphetamine, methylphenidate, atomoxetine, lisdexamfetamine, guanfacine, and clonidine. This search was then combined with an additional search that included the following outcome keywords: remission, relapse, remit, response, normal, normalization, recovery, and effectiveness. Results: Our search identified 102 publications. The majority (88.2% [90/102]) of these contained predefined criteria for treatment response. Predefined criteria for normalization and remission and/or relapse were presented in 4.9% (5/102), 12.7% (13/102), and 3.9% (4/102) of publications, respectively. There was a lack of consistency between the instruments used to measure outcomes as well as the criteria used to define treatment response, normalization, and remission as well as relapse. Conclusion: The therapeutic goals in treating ADHD should address optimal treatment outcomes that go beyond modest reductions of ADHD symptoms to include syndromatic, symptomatic, and functional remission. Future work should focus on reliable and valid tools to measure these outcomes in the clinical trial setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of these treatments will be augmented by monitoring both symptomatic and functional outcomes and promotingadherence 151 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [151]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma
Program, P., & theDiagnosis, T. E. P. O. (1997) · Cited by 4,926
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Self-citationFrank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“…have come to include the concept of remission and recovery, as well as freedom from impairment using well-defined criteria from diagnostic tools (American Psychiatric Association [APA], 1993; APA, 2000b; Andreasen et al., 2005; Depression Guideline Panel, 1993a, 1993b; Frank et al., 1991).”
MethodPearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000020190.45892.75 · Cited by 1,854
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
BARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498 · cited 4×
“Biederman et al. (2000) use the term to indicate that the patient has fewer than half the symptoms required for a diagnosis.”
BackgroundMethodInfluential
Research works printed but not linked: 9
- Biederman J., 2006, MedGenMed: Medscape General Medicine, 8, 12
- Depression Guideline Panel, 1993, Depression in primary care: Volume 1, diagnosis and detection
- Greenhill L. L., 2004, Paper presented at the American Psychiatric Association 2004 Annual Meeting
- Grizenko N., 2006, Journal of Psychiatry & Neuroscience, 31, 46
- Kemner J. E., 2004, Paper presented at the American Psychiatric Association 2004 Annual Meeting
- 10.1097/chi.0b013e318054e724 · DOI · Paper page
- Steele M., 2005, Paper presented at the American Psychiatric Association 2005 Annual Meeting
- Steele M., 2006, Canadian Journal of Clinical Pharmacology, 13, e50
- Wilens T. E., 1998, American Journal of Addiction, 7, 156
Cited by
Attention-deficit/hyperactivity disorder
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.20 · Cited by 1,479
Self-citationAttention-deficit/hyperactivity disorder
Faraone, S. V., Bellgrove, M. A., Brikell, I., Cortese, S., Hartman, C. A., Hollis, C., Newcorn, J. H., Philipsen, A., Polanczyk, G. V., Rubia, K., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00495-0 · Cited by 355
Self-citationChildress, A. C., & Sallee, F. R. (2014) · CNS Drugs · doi:10.1007/s40263-013-0130-6 · Cited by 98
“[20] defined functional remission as ‘‘having both symptom scores and functioning within the”
BackgroundPadilha, S. C., Virtuoso, S., Tonin, F. S., Borba, H. H. L., & Pontarolo, R. (2018) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1125-0 · Cited by 73
Is camouflaging unique for autism? A comparison of camouflaging between adults with autism and ADHD
van der Putten, W. J., Mol, A. J. J., Groenman, A. P., Radhoe, T. A., Torenvliet, C., van Rentergem, J. A. A., & Geurts, H. M. (2024) · Autism Research · doi:10.1002/aur.3099 · Cited by 54
Metadata
- Authors
- Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V.
- Affiliations
- University of Pennsylvania Health System (US)
- Mayo Clinic (US)
- University of Connecticut (US)
- Plymouth City Council (GB)
- SUNY Upstate Medical University (US)
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2013-02-19
- Volume
- 19
- Issue
- 2
- Pages
- 99-117
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2152960279
- Cited by
- 33
- References
- 175
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 1 · 2018: 1 · 2017: 4 · 2015: 4 · 2014: 5 · 2013: 1
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Attention Disorders (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Massachusetts General Hospital
- National Institutes of Health
- U.S. Food and Drug Administration
- State University of New York Upstate Medical University
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- attention deficit hyperactivity disorder, treatment goals, functional remission, relapse, treatment response criteria, outcome measures, stimulant pharmacotherapy, amphetamine, methylphenidate, atomoxetine, lisdexamfetamine, guanfacine, clonidine, chronic mental illness
- MeSH terms
- Atomoxetine Hydrochloride, Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Goals, Humans, Methylphenidate, Propylamines, Quality of Health Care, Guanfacine, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toward Quality Care in ADHD: Defining the Goals of Treatment. https://app.cochat.ai/papers/10.1177/1087054712473835
- The paper
- Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015). Toward Quality Care in ADHD: Defining the Goals of Treatment. Journal of Attention Disorders. https://doi.org/10.1177/1087054712473835
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.